Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 18, 2017, Pages 4751-4756

  Minamitani, Takeharu ^a   Ma, Yijie ^b,c   Zhou, Hufeng ^b,c   Kida, Hiroshi ^d   Tsai, Chao Yuan ^e   Obana, Masanori ^f   Okuzaki, Daisuke ^g   Fujio, Yasushi ^f   Kumanogoh, Atsushi ^d,h   Zhao, Bo ^b   Kikutani, Hitoshi ^e   Kieff, Elliott ^b,c   Gewurz, Benjamin E ^b   Yasui, Teruhito ^a  

^a 567 0085 Japan   (Japan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f OSAKA UNIVERSITY   (Japan)

^g OSAKA UNIVERSITY   (Japan)

^h JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT   (Japan)

Author keywords

Epstein Barr virus; LMP1; LMP2A; Plasmablast; Posttransplant lymphoproliferative disorder

Indexed keywords

B7 ANTIGEN; CD30 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; LATENT MEMBRANE PROTEIN 2A; LIPOPOLYSACCHARIDE; MACROPHAGE DERIVED CHEMOKINE; PROTEIN; PROTEIN PIM2; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CONTROLLED STUDY; GERMINAL CENTER; HODGKIN DISEASE; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMA CELL; PLASMABLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; SPLENIC B CELL; T LYMPHOCYTE; UPREGULATION; ANIMAL; B CELL LYMPHOMA; B LYMPHOCYTE; EPSTEIN BARR VIRUS; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MUTANT MOUSE STRAIN; PATHOLOGY;

ANIMALS; B-LYMPHOCYTES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; GERMINAL CENTER; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; KILLER CELLS, NATURAL; LYMPHOMA, B-CELL; MICE; MICE, MUTANT STRAINS; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES; VIRAL MATRIX PROTEINS;

EID: 85018341634     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1701836114     Document Type: Article

References (54)

1. Longnecker R, Kieff E, Cohen JI (2013) Epstein-Barr virus. Fields Virology, eds Knipe DM, Howley PM (Lippincott, Williams & Wilkins, Philadelphia), 6th Ed, Vol 2, pp 1898-1959.
2. Thorley-Lawson DA (2015) EBV persistence-introducing the virus. Curr Top Microbiol Immunol 390:151-209.
3. Babcock GJ, Hochberg D, Thorley-Lawson AD (2000) The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13:497-506.
4. Cohen JI, Fauci AS, Varmus H, Nabel GJ (2011) Epstein-Barr virus: An important vaccine target for cancer prevention. Sci Transl Med 3:107fs7.
5. LaCasce AS (2006) Post-transplant lymphoproliferative disorders. Oncologist 11: 674-680.
6. Powles T, et al. (2009) Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 27:884-890.
7. Cohen JI (2015) Primary immunodeficiencies associated with EBV disease. Curr Top Microbiol Immunol 390:241-265.
8. Longnecker R, Kieff E (1990) A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol 64:2319-2326.
9. Kieser A, Sterz KR (2015) The latent membrane protein 1 (LMP1). Curr Top Microbiol Immunol 391:119-149.
10. Wang F, et al. (1990) Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64:2309-2318.
11. Wang D, Liebowitz D, Kieff E (1985) An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831-840.
12. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R (1998) Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405-411.
13. Casola S, et al. (2004) B cell receptor signal strength determines B cell fate. Nat Immunol 5:317-327.
14. Cen O, Longnecker R (2015) Latent membrane protein 2 (LMP2). Curr Top Microbiol Immunol 391:151-180.
15. Merchant M, Longnecker R (2001) LMP2A survival and developmental signals are transmitted through Btk-dependent and Btk-independent pathways. Virology 291: 46-54.
16. Kwon K, et al. (2008) Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development. Immunity 28:751-762.
17. Muramatsu M, et al. (1999) Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 274(26):18470-18476.
18. Minamitani T, et al. (2015) Evasion of affinity-based selection in germinal centers by Epstein-Barr virus LMP2A. Proc Natl Acad Sci USA 112:11612-11617.
19. Zhang B, et al. (2012) Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell 148:739-751.
20. Cahir-McFarland ED, et al. (2004) Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 78:4108-4119.
21. Keller SA, et al. (2006) NF-kappaB is essential for the progression of KSHV-and EBVinfected lymphomas in vivo. Blood 107:3295-3302.
22. Shair KH, Raab-Traub N (2012) Transcriptome changes induced by Epstein-Barr virus LMP1 and LMP2A in transgenic lymphocytes and lymphoma. MBio 3:e00288-12.
23. Portis T, Dyck P, Longnecker R (2003) Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 102:4166-4178.
24. Swanson-Mungerson M, Bultema R, Longnecker R (2006) Epstein-Barr virus LMP2A enhances B-cell responses in vivo and in vitro. J Virol 80:6764-6770.
25. Groom JR, Luster AD (2011) CXCR3 ligands: Redundant, collaborative and antagonistic functions. Immunol Cell Biol 89:207-215.
26. Willenbrock K, et al. (2006) Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica 91: 596-604.
27. Green MR, et al. (2012) Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy. Clin Cancer Res 18:1611-1618.
28. Ouyang J, et al. (2011) Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood 117:4315-4322.
29. Mathas S, Hartmann S, Küppers R (2016) Hodgkin lymphoma: Pathology and biology. Semin Hematol 53:139-147.
30. Longnecker R, Druker B, Roberts TM, Kieff E (1991) An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol 65: 3681-3692.
31. Vrazo AC, ChauchardM, Raab-Traub N, Longnecker R (2012) Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice. PLoS Pathog 8:e1002662.
32. Wirtz T, et al. (2016) Mouse model for acute Epstein-Barr virus infection. Proc Natl Acad Sci USA 113:13821-13826.
33. Kulwichit W, et al. (1998) Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 95: 11963-11968.
34. Uchida J, et al. (1999) Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 286:300-303.
35. Panagopoulos D, Victoratos P, Alexiou M, Kollias G, Mosialos G (2004) Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus oncoprotein LMP1 in vivo. J Virol 78:13253-13261.
36. Dawson CW, George JH, Blake SM, Longnecker R, Young LS (2001) The Epstein-Barr virus encoded latent membrane protein 2A augments signaling from latent membrane protein 1. Virology 289:192-207.
37. Guasparri I, Bubman D, Cesarman E (2008) EBV LMP2A affects LMP1-mediated NFkappaB signaling and survival of lymphoma cells by regulating TRAF2 expression. Blood 111:3813-3820.
38. Shair KH, et al. (2012) Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) and LMP2A function cooperatively to promote carcinoma development in a mouse carcinogenesis model. J Virol 86:5352-5365.
39. Fish K, Chen J, Longnecker R (2014) Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. Blood 123:530-540.
40. Bultema R, Longnecker R, Swanson-Mungerson M (2009) Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis. Oncogene 28:1471-1476.
41. Bieging KT, Amick AC, Longnecker R (2009) Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis. Proc Natl Acad Sci USA 106: 17945-17950.
42. Ma SD, et al. (2017) LMP1 and LMP2A collaborate to promote Epstein-Barr virus (EBV)-induced B cell lymphomas in a cord blood-humanized mouse model but are not essential. J Virol 91(7):e01928-16.
43. Laichalk LL, Thorley-Lawson DA (2005) Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 79:1296-1307.
44. Castillo JJ, Bibas M, Miranda RN (2015) The biology and treatment of plasmablastic lymphoma. Blood 125:2323-2330.
45. Teichmann M, Meyer B, Beck A, Niedobitek G (2005) Expression of the interferoninducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma. J Pathol 206:68-75.
46. Teruya-Feldstein J, et al. (1997) The role of Mig, the monokine induced by interferongamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 90:4099-4105.
47. Liu QF, et al. (2010) Epstein-Barr virus-associated pneumonia in patients with posttransplant lymphoproliferative disease after hematopoietic stem cell transplantation. Transpl Infect Dis 12:284-291.
48. Kaan PM, Hegele RG, Hayashi S, Hogg JC (1997) Expression of bcl-2 and Epstein-Barr virus LMP1 in lymphocytic interstitial pneumonia. Thorax 52:12-16.
49. Haller A, von Segesser L, Baumann PC, Krause M (1995) Severe respiratory insufficiency complicating Epstein-Barr virus infection: case report and review. Clin Infect Dis 21:206-209.
50. Ivanov II, et al. (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126:1121-1133.
51. Dobin A, et al. (2013) STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29: 15-21.
52. Liao Y, Smyth GK, Shi W (2014) featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30:923-930.
53. Love MI, Anders S, Kim V, HuberW (2015) RNA-Seq workflow: Gene-level exploratory analysis and differential expression. F1000 Res 4:1070.
54. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550.